Smith & Nephew (LON:SN) Share Price Crosses Above 200 Day Moving Average – Here’s What Happened

Smith & Nephew plc (LON:SN)’s share price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 1,056.25 ($13.64) and traded as high as GBX 1,103.50 ($14.25). Smith & Nephew shares last traded at GBX 1,088.50 ($14.05), with a volume of 1,242,435 shares.

Wall Street Analyst Weigh In

Separately, JPMorgan Chase & Co. reiterated an “overweight” rating and set a GBX 1,180 ($15.24) price objective on shares of Smith & Nephew in a research report on Tuesday, January 14th.

Smith & Nephew Price Performance

The company has a 50 day moving average of GBX 1,061.24 and a two-hundred day moving average of GBX 1,055.74. The firm has a market cap of £11.89 billion, a P/E ratio of 39.06, a PEG ratio of 0.46 and a beta of 0.62. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22.

Smith & Nephew Increases Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, May 28th. Investors of record on Thursday, March 27th will be issued a dividend of $0.23 per share. This represents a yield of 1.61%. This is a boost from Smith & Nephew’s previous dividend of $0.14. The ex-dividend date is Thursday, March 27th. Smith & Nephew’s dividend payout ratio (DPR) is presently 104.41%.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.